Madrigal talked about this, his upcoming series I’m Dying Up Here and more. I didn’t realize until halfway through Shrimpin’ Ain’t Easy that you, more than most comics I’ve seen this ...

Marketing Madrigal’s Rezdiffra has launched a new MASH market, but ‘tremendous change’ is on the horizon By Ben Adams Nov 5, 2024 10:02am Madrigal Pharmaceuticals MASH GLP-1 Eli Lilly ...

Madrigal, who turns 28 on March 5, signed a one-year, $1.35 million contract with the Mets earlier this offseason. He's coming off a 2024 season for the Chicago Cubs in which he slashed .221/.280 ...

Madrigal Pharmaceuticals, Inc. has secured a $500 million senior secured credit facility from Blue Owl Capital to advance its pipeline focused on treating metabolic dysfunction-associated ...

In its first full quarter on the market, Madrigal Pharmaceuticals’ Rezdiffra, the first treatment for metabolic dysfunction-associated steatohepatitis (MASH), achieved sales of $14.6 million.

Madrigal's stock momentum is mixed, with a sharp decline over the last 3-6 months, but a strong performance over the 9-12 month period, showing a +133.40% increase.

Dolores Madrigal, right, with her son, Oren, in an undated photo during production for “No Más Bebés,” a 2015 documentary about the forced sterilization of women like Madrigal at Los Angeles ...

Madrigal separated his left shoulder during the 2020 season, which led to offseason surgery. His 2021 and 2024 seasons were both prematurely ended by injuries — a hamstring surgery and a left ...

Nick Madrigal's shoulder injury will require surgery and he will likely miss the entire season. Read more at MLB Trade Rumors.

CONSHOHOCKEN, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction ...